Prof. Dr. Ömer Fatih Ölmez

Immunotherapy in Lung and Thoracic Cancer

2024

DOI 10.69860/nobel.9786053359388.12 Source : ORCID

Immune checkpoints blockade therapies' efficacy and toxicity in patients with impaired renal function in metastatic bladder cancer.

Journal of Clinical Oncology, 2024

DOI 10.1200/jco.2024.42.4_suppl.594 Texte intégral en libre accèsSource : OpenAlex

Real-World Outcomes Of Lu-177 PSMA In Patients With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Single-Center Experience

Research Square, 2023

DOI 10.21203/rs.3.rs-3365105/v1 Texte intégral en libre accèsSource : OpenAlex

Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study

Biomolecules and Biomedicine, 2023

DOI 10.17305/bb.2023.9253 PMID 37289436 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

The Optimal Treatment Approaches and Prognostic Factors In Elderly Patients with Advanced Stage Biliary Tract Tumors

Acta Oncologica Turcica, 2023

DOI 10.5505/aot.2023.03708 Texte intégral en libre accèsSource : OpenAlex

Major and minor salivary gland cancers: A multicenter retrospective study

Head & Neck, 2023

DOI 10.1002/hed.27376 PMID 37084179 8 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy

Medicine, 2023

DOI 10.1097/md.0000000000033432 PMID 37058061 14 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide

Cancer Chemotherapy and Pharmacology, 2023

DOI 10.1007/s00280-023-04592-x PMID 37773537 8 citations (Europe PMC) Source : OpenAlex

Impact of SPARC expression on treatment response of pembrolizumab and brain metastasis in patients with metastatic non-small cell lung cancer

International Immunopharmacology, 2023

DOI 10.1016/j.intimp.2023.110947 PMID 37742369 5 citations (Europe PMC) Source : OpenAlex

SURVIVAL EFFECT OF PALLIATIVE RADIOTHERAPY IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER DEVELOPING OLIGO-PROGRESSION UNDER ANTIANDROGEN TREATMENT

Journal of Istanbul Faculty of Medicine / İstanbul Tıp Fakültesi Dergisi, 2023

DOI 10.26650/iuitfd.1211556 Texte intégral en libre accèsSource : OpenAlex

The Prognostic Role of Mismatch Repair Status and CDX-2 Expression with Inflammatory Markers and Pathological Risk Factors in Stage II and III Colon Cancer: Multicenter Real-Life Data

Journal of Gastrointestinal Cancer, 2023

DOI 10.1007/s12029-023-00953-0 PMID 37347353 1 citation (Europe PMC) Source : OpenAlex

The Efficacy And Safety of CDK 4/6 Inhibitors Plus Endocrine Therapy With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2- Negative Metastatic Breast Cancer Patients

Acta Oncologica Turcica, 2023

DOI 10.5505/aot.2023.00187 Texte intégral en libre accèsSource : OpenAlex

Erken Evre Triple Negatif Meme Kanserinde Sağkalım Sonuçları ve Prognostik Faktörler: Tek Merkez Deneyimi

Uludağ Üniversitesi Tıp Fakültesi Dergisi, 2023

DOI 10.32708/uutfd.1356458 Texte intégral en libre accèsSource : OpenAlex

THE IMPORTANCE OF CLINICAL AND LABORATORY PARAMETERS OF BONE MARROW METASTASIS IN PATIENTS WITH SOLID MALIGNANCY-SINGLE CENTER EXPERIENCE

Karya Journal of Health Science, 2023

DOI 10.52831/kjhs.1271864 Texte intégral en libre accèsSource : OpenAlex

Clinical assessment of HRD scoring in relation to PARPi response in terms of statistical guidance on reporting results for CDx tests evaluation.

Journal of Clinical Oncology, 2023

DOI 10.1200/jco.2023.41.16_suppl.e17597 Source : OpenAlex

Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?

Journal of Cancer Research and Clinical Oncology, 2023

DOI 10.1007/s00432-023-05190-3 PMID 37480524 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study

Acta Oncologica, 2023

DOI 10.1080/0284186x.2023.2202330 PMID 37083566 3 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Clinicopathological and Survival Characteristics of Mismatch Repair Status and PD-1 Expression in Serous Ovarian Cancer

Journal of College of Physicians And Surgeons Pakistan, 2023

DOI 10.29271/jcpsp.2023.06.666 PMID 37300263 Texte intégral en libre accèsSource : OpenAlex

Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practice

Clinical Genitourinary Cancer, 2023

DOI 10.1016/j.clgc.2022.11.019 PMID 36641357 2 citations (Europe PMC) Source : ORCID

The Prevalence of Drug-Drug Interactions and Reported Therapy Related Side Effects in Oncology Out-Patients

Clinical and Experimental Health Sciences, 2023

DOI 10.33808/clinexphealthsci.1099582 5 citations (OpenAlex) Texte intégral en libre accèsSource : ORCID

The modified Glasgow prognostic score (MGPS) and the mortality prediction model II (MPM II) can predict mortality in patients with breast cancer admitted to intensive care: A retrospective cohort study

Journal of Surgery and Medicine, 2023

DOI 10.28982/josam.7606 Texte intégral en libre accèsSource : ORCID

Relationship between the change in tumour-infiltrating lymphocyte level and residual tumour after neoadjuvant chemotherapy in patients with locally advanced breast cancer

Journal of Chemotherapy, 2023

DOI 10.1080/1120009x.2023.2247207 PMID 37599454 2 citations (OpenAlex) Source : OpenAlex

Survival outcomes of patients with oligometastatic non-small cell lung cancer who were treated with radical therapy: a multicenter analysis

TURKISH JOURNAL OF MEDICAL SCIENCES, 2023

DOI 10.55730/1300-0144.5659 PMID 38031948 2 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

Comparison of objective response rate and long-term overall survival in patients with treated immune checkpoint inhibitors in metastatic urothelial carcinoma.

Journal of Clinical Oncology, 2023

DOI 10.1200/jco.2023.41.6_suppl.481 Source : OpenAlex

The SOCS-1 -1478CA/del functional polymorphism (rs33989964) is associated with gastric cancer but is unrelated to overall survival

Molecular Biology Reports, 2023

DOI 10.1007/s11033-023-08296-6 PMID 36781608 2 citations (OpenAlex) Source : OpenAlex

Impact of SPARC expression on pembrolizumab treatment response and prognostic role in advanced stage non-small cell lung cancer.

Journal of Clinical Oncology, 2023

DOI 10.1200/jco.2023.41.16_suppl.e21042 Source : OpenAlex

The relationship between the change with neoadjuvant chemotherapy in the tumor-infiltrating lymphocyte (TIL) expressions and pathological response in breast cancer patients.

Journal of Clinical Oncology, 2023

DOI 10.1200/jco.2023.41.16_suppl.3114 Texte intégral en libre accèsSource : OpenAlex

Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer

Current Medical Research and Opinion, 2022

DOI 10.1080/03007995.2022.2108619 PMID 35916475 4 citations (Europe PMC) Source : OpenAlex

Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group

Journal of Cancer Research and Clinical Oncology, 2022

DOI 10.1007/s00432-022-04087-x PMID 35689097 11 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).

Journal of Clinical Oncology, 2022

DOI 10.1200/jco.2022.40.16_suppl.e12610 2 citations (OpenAlex) Source : OpenAlex

The comparison of local tumor control after microwave ablation, surgical resection and combined treatment for colorectal liver metastases

Journal of Mind and Medical Sciences, 2022

DOI 10.22543/7674.91.p125132 2 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).

Bursa Uludag University - AVESIS, 2022

Source : OpenAlex

High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer

Journal of Turkish Society of Obstetric and Gynecology, 2022

DOI 10.4274/tjod.galenos.2022.59558 PMID 36149309 5 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Response to first-line chemotherapy regimen is associated with efficacy of ımmune checkpoint blockade therapies in patients with metastatic urothelial carcinoma

International Journal of Clinical Oncology, 2022

DOI 10.1007/s10147-021-02072-x PMID 34762201 5 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Neutrophil-to-Lymphocyte Ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as Prognostic Markers in Patients With Extensive-Stage Small Cell Lung Carcinoma Treated with Atezolizumab in Combination with Chemotherapy: Single Center Experience

Social Science Research Network, 2022

DOI 10.2139/ssrn.3977779 1 citation (Semantic Scholar) Texte intégral en libre accèsSource : ORCID

Pretreatment platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio as a predictor of pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: single center experience from Turkey

Anti-Cancer Drugs, 2022

DOI 10.1097/cad.0000000000001389 PMID 36206103 11 citations (Europe PMC) Source : ORCID

Long-term outcome and safety in patients treated with immune checkpoint blockade therapies for urothelial carcinoma: Experience from real-world clinical practice.

Journal of Clinical Oncology, 2022

DOI 10.1200/jco.2022.40.6_suppl.474 1 citation (OpenAlex) Source : OpenAlex

The modified glasgow prognostic score (MGPS) and the mortality prediction MODEL II (MPM II) CAN predict mortality in patients with breast cancer admitted to intensive care: A retrospective cohort study.

Journal of Clinical Oncology, 2022

DOI 10.1200/jco.2022.40.16_suppl.e13055 Source : OpenAlex

Treatment Management Of Leptomeningeal And Brain Metastases As A Firt Reccurence Site In A Case With Germ Cell Testicular Cancer

Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi, 2022

DOI 10.5505/deutfd.2022.69926 Texte intégral en libre accèsSource : OpenAlex

Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study

Cancer Investigation, 2021

DOI 10.1080/07357907.2021.2017952 PMID 34894960 3 citations (Europe PMC) Source : OpenAlex

P40.20 Real-Life Analysis of Immunotherapy as the Second or Later Lines Treatment in Patients With Metastatic Non-Small Cell Lung Cancer

Journal of Thoracic Oncology, 2021

DOI 10.1016/j.jtho.2021.08.457 Texte intégral en libre accèsSource : OpenAlex

Real-life analysis of immunotherapy as the second or later lines treatment in patients with metastatic non-small cell lung cancer

Acta Oncologica Turcica, 2021

DOI 10.5505/aot.2021.26576 Texte intégral en libre accèsSource : OpenAlex

Platelet to lymphocyte ratio is associated with tumor localization and outcomes in metastatic colorectal cancer

Medicine, 2021

DOI 10.1097/md.0000000000027712 PMID 34871263 14 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Prognostic significance of primary tumor localization in patients with metastatic colorectal cancer: Is it beneficial to select targeted treatment? Real-life experience from Turkey.

PubMed, 2021

PMID 34761599 Source : OpenAlex

Serous Epithelial Ovarian Cancer: Retrospective Analysis of 260 Cases

Aegean Journal of Obstetrics and Gynecology, 2021

DOI 10.46328/aejog.v3i1.83 5 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

P84.03 GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patients

Journal of Thoracic Oncology, 2021

DOI 10.1016/j.jtho.2021.01.1202 Texte intégral en libre accèsSource : OpenAlex

Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab

International Journal of Clinical Oncology, 2021

DOI 10.1007/s10147-021-01936-6 PMID 34023933 14 citations (Europe PMC) Source : ORCID

The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: a multicenter study

International Journal of Colorectal Disease, 2021

DOI 10.1007/s00384-021-03888-9 PMID 33586012 28 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma.

Journal of Clinical Oncology, 2021

DOI 10.1200/jco.2021.39.6_suppl.409 1 citation (OpenAlex) Source : OpenAlex

Triple‐negative breast cancer presented with metastasis to the heart as first sign of recurrence

The Breast Journal, 2020

DOI 10.1111/tbj.14091 PMID 33070447 Source : OpenAlex